Noopept Capsules
Noopept Capsules USA — Capsules
Nootropic Dipeptide Compound
Noopept is the common designation for N-phenylacetyl-L-prolylglycine ethyl ester, a synthetic dipeptide ester with the molecular formula C17H22N2O4 and a molecular weight of 318.4. It is supplied in capsule form strictly for laboratory research use.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Noopept is the common designation for N-phenylacetyl-L-prolylglycine ethyl ester, a synthetic dipeptide ester with the molecular formula C17H22N2O4 and a molecular weight of 318.4. It is supplied in capsule form strictly for laboratory research use.
In scientific literature, Noopept has been examined in rodent models addressing neurotrophic factor expression, hippocampal neuron signaling, oxidative stress markers, and transcription factor activity. Its physicochemical and structural characteristics have also been described as a distinct analytical subject.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for this lot is being finalised and will be published here as soon as the lab returns it.
Noopept is a proline-containing dipeptide ester developed as a structural analogue within the racetam-adjacent nootropic class. Reported mechanistic work in animal and cell models has centred on expression of nerve growth factor and brain-derived neurotrophic factor in rat hippocampus, activation of the hypoxia-inducible transcription factor HIF-1 in cultured cells, and electrophysiological effects on CA1 pyramidal neurons that appear in hippocampal slice experiments to involve alpha-7 nicotinic acetylcholine receptors on interneurons. Separate cell work reported that the compound did not stimulate proliferation, a finding used to distinguish its activity from growth-factor-like mitogenic signaling.
Research endpoints evaluated in the published record include behavioural measures of learning and memory in diabetic rats, histopathological scoring of ocular, pancreatic and renal tissue in streptozotocin-induced models, parameters of the incretin system in experimental diabetes, markers of DNA damage in modeled prediabetes, TRPV1-linked oxidative neurotoxicity and neuropathic pain measures, spinal microglial BDNF and pro-BDNF expression in persistent inflammation models, immunopharmacological assays, and motor and mitochondrial pathology in PINK1 knockout rats. The bulk of this record is preclinical, with much of the mechanistic work originating from a small number of research groups.
Noopept was described in the Russian pharmacological literature in the early 2000s as a novel dipeptide designed to combine nootropic and neuroprotective profiles, and the earliest characterisations of its activity come from that body of work. Subsequent publications from the same lineage extended the investigation to neurotrophic factor expression in rat hippocampus and to immunopharmacological assays.
From roughly the 2010s onward, work on the compound broadened to groups outside its original setting, with reports on incretin parameters and DNA damage in experimental diabetes and prediabetes, histopathology in streptozotocin-induced diabetic rats, TRPV1-mediated neuropathic pain and hippocampal oxidative endpoints, spinal microglial BDNF signaling in persistent inflammation, and parkinsonian pathology in a PINK1 knockout rat model. More recent analytical work has characterised the compound as an active pharmaceutical ingredient in physicochemical and structural terms. Clinical documentation in the English-language literature remains sparse relative to this preclinical volume.
Laboratory investigations into Noopept appear within neurotrophic signaling frameworks, hippocampal electrophysiology, experimental diabetes and prediabetes models, nociception and oxidative stress research, and models of parkinsonian pathology. Reported endpoints include NGF and BDNF expression, HIF-1 transcription factor activation, alpha-7 nicotinic receptor-dependent effects on CA1 pyramidal neurons, TRPV1 channel involvement, tissue histopathology, and DNA damage markers, all under controlled preclinical and in vitro conditions.
5 of the 5 areas below are addressed directly by a paper cited on this page.
Neurotrophic factor expression models (NGF, BDNF)
Addressed on this page by Ostrovskaya 2008, Zainullina 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Ostrovskaya, RU. et al. (2008) — Noopept stimulates the expression of NGF and BDNF in rat hippocampus
- Zainullina, LF. et al. (2020) — Cognitive Enhancer Noopept Activates Transcription Factor HIF-1
Hippocampal slice electrophysiology and α7 nAChR signaling
Addressed on this page by Kondratenko 2022, Düzova 2021. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Kondratenko, RV. et al. (2022) — Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat
- Düzova, H. et al. (2021) — Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats
Experimental diabetes and prediabetes models
Addressed on this page by Düzova 2021. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Düzova, H. et al. (2021) — Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats
TRPV1-linked nociception and oxidative stress research
Addressed on this page by Düzova 2021. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Düzova, H. et al. (2021) — Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats
Transcription factor HIF-1 activation studies
Addressed on this page by Zainullina 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Zainullina, LF. et al. (2020) — Cognitive Enhancer Noopept Activates Transcription Factor HIF-1
The references section of this page cites 6 primary papers published between 2002 and 2022 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Noopept Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Noopept Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Noopept Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under neurotrophic factor expression models (NGF, BDNF), hippocampal slice electrophysiology and α7 nAChR signaling and experimental diabetes and prediabetes models.
The 6 papers cited on this page, published between 2002 and 2022 (4 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Noopept Capsules is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Noopept Capsules in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Storage
- Cool, dry, away from direct light
- Humidity
- Keep sealed; capsule shells are hygroscopic
- Reconstitution
- Not applicable — supplied pre-measured
- Format
- Oral capsule
Noopept Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
- 1 × sealed capsule bottle (20mg per capsule / Single Bottle - Pack of 60), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Laboratory consumables of any kind
- Dosing, administration or protocol guidance of any kind
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of Noopept. Independent third-party analysis verifies purity, identity, and net content per batch.
The container holds only the encapsulated compound. Any laboratory materials required for preparation, extraction, or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Noopept stimulates the expression of NGF and BDNF in rat hippocampus
PubMedEffect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat
PubMedNoopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in Rats
PubMedIntranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats
PubMedRelated
You May Also Like
Fisetin-Derived Research Compound CMS-121 is a synthetic small molecule derived from the plant flavonoid fisetin, produced for laboratory research use only. It is supplied in capsule form for controlled experimental work and is not intended for any other application.
$29.99
Methylated Beta-Carboline Alkaloid 9-Me-BC (9-methyl-beta-carboline) is a small methylated beta-carboline alkaloid studied in neurochemical research models. It is supplied in capsule form strictly for laboratory research use.
$64.99
Uncharacterised Research Compound Compound-7P is supplied as capsules for laboratory research use. The designation "Compound-7P" is a non-systematic label and does not correspond to a single identified chemical entity in the published chemical or pharmacological literature. No PubChem record matches the name, and no molecular formula, sequence or structural profile was supplied with it.
$49.99
Redox-Active Flavin Analogue 5-Deazaflavin is a synthetic analogue of the flavin ring system in which the nitrogen at position 5 of the isoalloxazine core is replaced by carbon. The parent heterocycle (C11H7N3O2, MW 213.19) and its substituted derivatives are produced for laboratory research and are handled within controlled experimental environments.
$59.99